Search Results
Nov 12, 2025, 07:58 ET Commercial Metals Company Announces Proposed Private Offering of $2,000 Million Senior Notes
IRVING, Texas, Nov. 12, 2025 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) ("CMC" or the "Company") announced today that it intends to offer to sell, subject to market and other conditions, $2,000 million in aggregate
More news about: Commercial Metals Company
Nov 12, 2025, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 19:54 ET TLX INVESTOR ALERT: Telix Pharmaceuticals Ltd. Investors with Substantial Losses Have Opportunity to Lead the Telix Class Action Lawsuit - RGRD Law
the Biologics License Application for its product TLX250-CDx, which identified "deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package." The FDA additionally "documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will
More news about: Robbins Geller Rudman & Dowd LLP
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
manufacturing can look like," said Dr. Alessandra Rispoli, Chief Executive Officer at Ascend Advanced Therapies. "By integrating this enhancer into our CMC offering, we enable our partners and customers to achieve higher yield, reduced cost per dose, and faster scalability, translating scientific innovation
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
manufacturing can look like," said Dr. Alessandra Rispoli, Chief Executive Officer at Ascend Advanced Therapies. "By integrating this enhancer into our CMC offering, we enable our partners and customers to achieve higher yield, reduced cost per dose, and faster scalability, translating scientific innovation
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend stellt proprietäre Enhancer vor, die die AAV-Ausbeute deutlich verbessern, ohne die Qualität zu beeinträchtigen
zu definieren", sagte Dr. Alessandra Rispoli, Chief Executive Officer bei Ascend Advanced Therapies. „Durch die Integration dieses Enhancers in unser CMC-Angebot ermöglichen wir unseren Partnern und Kunden höhere Erträge, geringere Kosten pro Dosis und eine schnellere Skalierbarkeit, wodurch wissenschaftliche
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend dévoile des activateurs propriétaires qui augmentent significativement les rendements en AAV sans compromis sur la qualité
de haute qualité », a déclaré le Dr Alessandra Rispoli, directeur général d'Ascend Advanced Therapies. « En intégrant cet activateur à notre offre de CMC, nous permettons à nos partenaires et à nos clients d'obtenir un rendement plus élevé, un coût par dose réduit et une évolutivité plus rapide, traduisant
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
manufacturing and the development of the first tumor-specific CAR-T for CLL. These discussions emphasized a central message: CMC capabilities are not merely operational necessities – they are strategic enablers. Cellex's integrated approach to process design, manufacturing analytics,
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Das Cellex-Symposium 2025 führt internationale Experten zusammen, die über die Entwicklungen im Bereich der Zell- und Gentherapie diskutieren
die Entwicklung des ersten tumorspezifischen CAR-T für CLL vorstellten. Diese Diskussionen betonten eine zentrale Botschaft: CMC-Fähigkeiten sind nicht nur operative Notwendigkeiten, sondern auch strategische Voraussetzungen. Der integrierte Ansatz von Cellex bei der Prozessentwicklung,
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
manufacturing and the development of the first tumor-specific CAR-T for CLL. These discussions emphasized a central message: CMC capabilities are not merely operational necessities – they are strategic enablers. Cellex's integrated approach to process design, manufacturing analytics,
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025: debate sobre el campo en evolución de la terapia celular y génica
el desarrollo de la primera célula CAR-T específica para CLL. Estos debates enfatizaron un mensaje central: las capacidades de CMC no son meras necesidades operativas, sino facilitadores estratégicos. El enfoque integrado de Cellex para el diseño de procesos, el análisis de la fabricación
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Le Symposium Cellex 2025 réunit des experts internationaux pour discuter de l'évolution du domaine de la thérapie cellulaire et génique
du premier CAR-T spécifique à la tumeur pour la LLC. Ces discussions ont mis l'accent sur un message central : les capacités CMC ne sont pas simplement des nécessités opérationnelles, elles sont des catalyseurs stratégiques. L'approche intégrée de Cellex en matière de conception
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase
More news about: Acurx Pharmaceuticals, Inc.
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
several in vivo tumor animal models. By advancing breakthroughs in multi-functional, innovative molecular configurations in R&D and improving CMC manufacturing processes, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit:
More news about: HanchorBio Inc.
Nov 07, 2025, 07:55 ET KOPPERS REPORTS THIRD QUARTER 2025 RESULTS
offset by $1.6 million of lower logistics costs and selling, general and administrative expenses, and higher royalty income. CMC net sales decreased mainly due to volume decreases of phthalic anhydride of $19.6 million as the company discontinued production, lower volumes and lower
More news about: KOPPERS HOLDINGS INC.
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit:
More news about: HanchorBio Inc.
Nov 04, 2025, 17:31 ET Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
involved in itch signaling pathways. Phase I data support advancement to Phase II in the US, following positive feedback from the FDA and completion of CMC activities. The upcoming Phase II trial will target moderate-to-severe pruritus in PBC (referred to as a hepatic impairment study) and is expected to
More news about: DelveInsight Business Research, LLP
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
totaled $83.0 million compared to $74.2 million for the three months ended June 30, 2025. The increase was primarily driven by higher clinical trial and CMC manufacturing expenses to support our programs. General and administrative (G&A) expenses for the three months ended September
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for November 2025
Recruitment with Precision Feasibility and RWD PHARMA MANUFACTURING & SUPPLY CHAINNov 5 - CMC Development Strategies to Prevent Rework and DelaysNov 6 - Beyond the bench: The advantages of GMP over USP compounding in early phase developmentNov
More news about: Xtalks
Nov 03, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
helping SonomaBio transition from open flask-based technology to the proven, commercially viable G-Rex platform—an essential step in preparing their CMC for commercial readiness," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of their grant, SonomaBio will
More news about: Bio-Techne Corporation
Oct 30, 2025, 12:00 ET ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
/PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows
More news about: ChemDiv
Oct 30, 2025, 08:30 ET Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic Proteins, Upcoming Webinar Hosted by Xtalks
market, as late-phase chemistry, manufacturing and controls (CMC) programs often face delays that jeopardize speed to market and strain development resources. This webinar explores strategies for reducing late-phase CMC timelines for mammalian and microbial-derived therapeutic
More news about: Xtalks
Oct 30, 2025, 08:00 ET ChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer
developability from day one, we're seeing cleaner, faster paths into scale‑up and CMC." said Roman Timakhov, Research Director at ChemDiv. Collaboration progress toward scale‑up and CMC Following demonstration of a differentiated reversible
More news about: ChemDiv
Oct 30, 2025, 08:00 ET Zifo Democratizes Data Access for Scientists through its AI-Powered Conversational Dashboard
's Solution Solves it The Zifo Conversational Dashboard directly solves major pain points across the R&D, CMC, and Manufacturing segments of the value chain:
More news about: Zifo Technologies
Oct 30, 2025, 04:16 ET 新橋生物子公司 Visara 將 VIS-101 在大中華區及部分亞洲國家的獨家許可轉讓給雲頂新耀
雲頂新耀是一家專注於創新藥和疫苗研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業從事過高質量研發、臨床開發、藥政事務、化學製造與控制（ CMC）、業務發展和商業化運營，擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合，公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。 有關更多信息，請訪問公司網站：
More news about: 新橋生物